Lung Cancer Clinical Trials in Los Angeles

Showing 361-380 of 597 trials

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

NCT03265080

This is a Phase 1, open-label, multicenter study of ADXS-NEO administered alone and in combination with pembrolizumab in participants with select advanced or metastatic solid tumors. This study will be performed in 2 phases, a safety phase (Part A and Part B) and an efficacy phase (Part C).

Colon Cancer MetastaticHead and Neck Cancer MetastaticMetastatic Non-Small Cell Lung Cancer+2 more

Advaxis, Inc.13 participantsStarted Mar 2018

Scottsdale, Arizona, United States • Los Angeles, California, United States • New Orleans, Louisiana, United States +2 more locations

COMPLETEDPhase 2< 1 mile

Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

NCT03090737

A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer

Non-Small Cell Lung Cancer

Bristol-Myers Squibb129 participantsStarted Jun 2017

Birmingham, Alabama, United States • Los Angeles, California, United States • Billings, Montana, United States +14 more locations

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

Lung Cancer Trials in Other Cities

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC

A Study of LY3023414 in Participants With Advanced Cancer

Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC

Brigatinib Before Brain Irradiation Trial (B3i Trial)

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Other Conditions in Los Angeles